Cytokinetics CYTK
$50.78 −$0.68 (-1.32%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $52.48 +3.35%
Open$51.27
Prev close$51.46
Day range$50.60 – $53.45
Volume1.43M
Market cap$7.07B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$47.56M+2,356.5% YoY
Operating profit-$167.09M-0.2% YoY
Net profit-$190.07M+37.9% YoY
Diluted EPS-$1.37+46.3% YoY
Free cash flow-$124.72M-6.7% YoY
Operating cash flow-$124.02M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin95.3%
Operating margin-625.2%
Net margin-686.6%
Return on assets-47.7%
Current ratio3.36
Liabilities / assets117.6%
Cash & investments$1.13B
Total debt$1.25B
Net cash (debt)-$121.15M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $47.56M | $28.62M | $19.36M | $88.04M | $17.76M |
| Total Operating Revenue | $47.56M | $28.62M | $19.36M | $88.04M | $17.76M |
| Cost of Revenue | $2.22M | $5.59M | $2.55M | – | – |
| Gross Profit | $45.34M | $23.03M | $16.80M | – | – |
| Operating Expense | $212.43M | $202.20M | $200.42M | $700.30M | $202.05M |
| Selling and Admin Expenses | $113.14M | $104.40M | $104.90M | $284.27M | $91.72M |
| -General & Admin Expense | $113.14M | – | – | $284.27M | $91.72M |
| Research & Development | $99.29M | $97.81M | $95.53M | $416.03M | $110.33M |
| Operating Profit | -$167.09M | -$179.17M | -$183.62M | -$612.26M | -$178.37M |
| Net Non-Operating Interest Income (Expense) | -$22.58M | -$20.89M | -$22.31M | -$55.45M | -$18.87M |
| Non-Operating Interest Income | $15.90M | $13.94M | $11.02M | $48.42M | $11.47M |
| Non-Operating Interest Expense | $38.48M | $34.83M | $33.34M | $103.87M | $30.34M |
| Other Income (Expense) | -$400,000.00 | $1.30M | -$100,000.00 | -$117.25M | $14.20M |
| Gain on Sale of Security | -$600,000.00 | -$1.10M | $1.50M | $4.20M | $900,000.00 |
| Special Income (Charges) | $0.00 | – | – | -$121.25M | $0.00 |
| Other Non-Operating Income (Expenses) | $200,000.00 | $2.40M | -$1.60M | -$200,000.00 | $13.30M |
| Pretax Profit | -$190.07M | -$198.76M | -$206.03M | -$784.96M | -$183.03M |
| Net Profit | -$190.07M | -$198.76M | -$206.03M | -$784.96M | -$183.03M |
| Profit from Continuing Operations | -$190.07M | -$198.76M | -$206.03M | -$784.96M | -$183.03M |
| Net Income to Parent Company | -$190.07M | -$198.76M | -$206.03M | -$784.96M | -$183.03M |
| Net Income to Common Stockholders | -$190.07M | -$198.76M | -$206.03M | -$784.96M | -$183.03M |
| Basic EPS | -$1.37 | -$1.50 | -$1.67 | -$6.54 | -$1.50 |
| Diluted EPS | -$1.37 | -$1.50 | -$1.67 | -$6.54 | -$1.50 |
| -Less:Other Special Charges | – | – | – | $121.25M | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.82B | $1.92B | $1.27B | $1.42B | $1.42B |
| Total Current Assets | $1.19B | $1.21B | $839.47M | $916.98M | $916.98M |
| Cash and Cash Equivalents & Short-Term Investments | $1.13B | $1.17B | $818.55M | $882.22M | $882.22M |
| -Cash and Cash Equivalents | $203.43M | $255.27M | $129.84M | $122.52M | $122.52M |
| -Short Term Investments | $926.59M | $910.42M | $688.71M | $759.70M | $759.70M |
| Receivables | $33.89M | $24.43M | $6.83M | $17.76M | $17.76M |
| -Accounts Receivable | $33.89M | $24.43M | $6.83M | $17.76M | $17.76M |
| Inventory | $807,000.00 | $380,000.00 | $154,000.00 | – | – |
| Other Current Assets | $22.43M | $17.99M | $13.93M | $16.99M | $16.99M |
| Total Non-Current Assets | $637.63M | $716.06M | $434.01M | $507.56M | $507.56M |
| Net PPE | $147.69M | $151.81M | $156.98M | $155.17M | $155.17M |
| -Gross PPE | $147.69M | $151.81M | $156.98M | $202.47M | $202.47M |
| Investments and Advances | $453.63M | $538.32M | $254.72M | $335.05M | $335.05M |
| -Available for Sale Securities | $453.63M | $538.32M | $254.72M | $335.05M | $335.05M |
| Other Non-Current Assets | $36.31M | $25.94M | $22.31M | $17.34M | $17.34M |
| Total Liabilities | $2.15B | $2.10B | $2.10B | $2.08B | $2.08B |
| Total Current Liabilities | $353.42M | $181.43M | $199.19M | $202.45M | $202.45M |
| Payables | $25.96M | $20.51M | $24.71M | $22.34M | $22.34M |
| -Accounts Payable | $25.96M | $20.51M | $24.71M | $22.34M | $22.34M |
| Current Accrued Expenses | $43.10M | $42.52M | $41.51M | $38.13M | $38.13M |
| Short-Term Debt and Capital Lease Obligation | $195.79M | $48.40M | $65.77M | $60.29M | $60.29M |
| -Current Debt | $174.40M | $27.36M | $44.81M | $41.18M | $41.18M |
| -Current Capital Lease Obligation | $21.39M | $21.04M | $20.96M | $19.11M | $19.11M |
| Current Deferred Liabilities | $1.65M | $1.65M | $1.65M | $1.61M | $1.61M |
| Other Current Liabilities | $39.14M | $34.00M | $38.19M | $34.93M | $34.93M |
| Total Non-Current Liabilities | $1.79B | $1.92B | $1.90B | $1.88B | $1.88B |
| Long Term Debt and Capital Lease Obligation | $1.08B | $1.22B | $1.22B | $1.22B | $1.22B |
| -Long Term Debt | $977.10M | $1.12B | $1.12B | $1.12B | $1.12B |
| -Long Term Capital Lease Obligation | $99.67M | $102.43M | $105.24M | $107.97M | $107.97M |
| Other Non-Current Liabilities | $715.76M | $694.45M | $677.91M | $657.76M | $657.76M |
| Total Equity | -$321.17M | -$173.49M | -$826.57M | -$659.63M | -$659.63M |
| Stockholders' Equity | -$321.17M | -$173.49M | -$826.57M | -$659.63M | -$659.63M |
| Capital Stock | $139,000.00 | $138,000.00 | $124,000.00 | $123,000.00 | $123,000.00 |
| -Common Stock | $139,000.00 | $138,000.00 | $124,000.00 | $123,000.00 | $123,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $3.77B | $3.72B | $2.87B | $2.83B | $2.83B |
| Retained Earnings | -$4.08B | -$3.89B | -$3.69B | -$3.49B | -$3.49B |
| Gains/Losses Not Affecting Retained Earnings | -$8.39M | -$3.83M | -$1.61M | $630,000.00 | $630,000.00 |
| -Accumulated Depreciation | – | – | – | -$47.30M | -$47.30M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$124.02M | -$159.84M | -$145.46M | -$510.01M | -$142.65M |
| Net cash flow from continuing operations | -$124.02M | -$159.84M | -$145.46M | -$510.01M | -$142.65M |
| Net Income from Continuing Operations | -$190.07M | -$198.76M | -$206.03M | -$784.96M | -$183.03M |
| Gain/Loss from Continuing Operations | $537,000.00 | $1.04M | -$1.56M | -$4.23M | -$908,000.00 |
| Depreciation & Depletion & Amortization | $3.65M | $3.63M | $3.38M | $10.13M | $2.86M |
| Other Non-Cash Items | $29.92M | $23.78M | $28.58M | $192.39M | $9.77M |
| Change in Working Capital | -$2.78M | -$25.24M | -$219,000.00 | -$35.63M | -$1.85M |
| -Change in Receivables | -$9.46M | -$17.61M | $10.94M | -$1.11M | -$15.96M |
| -Change in Inventory | -$9.29M | -$2.26M | -$3.57M | – | – |
| -Change in Prepaid Assets | -$5.11M | -$4.84M | $2.06M | -$2.93M | -$4.20M |
| -Change in Payables and Accrued Expense | $30.27M | $5.28M | -$4.69M | $36.27M | $26.06M |
| -Change in Other Current Liabilities | -$9.19M | -$5.81M | -$4.99M | -$17.09M | -$7.75M |
| -Change In Other Working Capital | $0.00 | $0.00 | $41,000.00 | -$50.76M | $0.00 |
| Net cash flow from investing | $67.93M | -$507.00M | $145.49M | $16.67M | -$71.19M |
| Net Cash Flow from Continuing Investing Activities | $67.93M | -$507.00M | $145.49M | $16.67M | -$71.19M |
| Net PPE Purchase and Sale | -$700,000.00 | -$4.33M | -$5.93M | -$24.81M | -$5.64M |
| Net Investment Purchase and Sale | $68.63M | -$502.66M | $151.42M | $41.47M | -$65.55M |
| Financing Cash Flow | $4.80M | $792.86M | $7.77M | $524.46M | $110.71M |
| Net Cash Flow from Continuing Financing Activities | $4.80M | $792.86M | $7.77M | $524.46M | $110.71M |
| Net Issuance Payments Of Debt | -$5.41M | -$3.59M | -$2.74M | $315.95M | -$2.72M |
| Net Common Stock Issuance | -$1,000.00 | – | – | $0.00 | $0.00 |
| Proceeds from Stock Option Exercised | $12.41M | $38.00M | $11.35M | $35.98M | $14.65M |
| Net Other Financing Charges | -$2.20M | -$1.70M | -$841,000.00 | $172.53M | $98.78M |
| Ending Cash Balance | $206.53M | $258.38M | $132.95M | $125.63M | $125.63M |
| Net Change in Cash | -$51.29M | $126.02M | $7.81M | $31.12M | -$103.14M |
| Beginning Cash Balance | $258.38M | $132.95M | $125.63M | $95.23M | $228.58M |
| Effect of Exchange Rate Changes | -$559,000.00 | -$595,000.00 | -$483,000.00 | -$715,000.00 | $191,000.00 |
| Free Cash Flow | -$124.72M | -$164.17M | -$151.39M | -$534.82M | -$148.30M |
No comments yet — be the first to weigh in on CYTK.
Sign in to join the discussion.